Kathryn E. Wengel, EVP, Chief TO and Risk Officer, has engaged in a mix of buying and selling activity across two companies—Johnson & Johnson (JNJ) and Laboratory Corporation of America (LH)—based on SEC Form 4 filings. Her transactions show a clear net selling bias, with total sales of $13.9 million outweighing purchases of $7.2 million. The bulk of her activity has been in JNJ, including a significant $6.5 million acquisition on February 6, 2026, followed by a $3.97 million sale the same day. Earlier, on February 12, 2024, she sold $1.1 million in JNJ shares, preceded by a $4.3 million purchase three days prior. Smaller transactions, such as a $791,000 sale on February 15, 2026, and a $525,000 sale on February 13, 2024, suggest periodic adjustments to her holdings.
Wengel’s trades in LH appear limited, with no reported monetary value in recent transactions, indicating they may involve non-monetary events like option exercises or grants. The absence of recent buys or sells in 2026 suggests a pause in active trading after her February JNJ transactions. The pattern reflects a tendency to monetize portions of her JNJ holdings while maintaining a long-term position, with no recent activity signaling a shift in strategy. The data underscores a disciplined approach, balancing accumulation with opportunistic divestments.
AI-assisted summary